Biotech | September 29, 2025
DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
The new site enables end-to-end production of viral vector gene therapies
The new site enables end-to-end production of viral vector gene therapies
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
